A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer

Gastrointestinal Cancer Research

Volumn 5, Issue 3, 2012, Pages 77-83

  Moss, Rebecca A ^a   Moore, Dirk ^b   Mulcahy, Mary F ^c   Nahum, Kenneth ^d   Saraiya, Biren ^a   Eddy, Simantini ^e   Kleber, Martin ^e   Poplin, Elizabeth A ^a  

^a Division of Medical Oncology   (United States)

^b Department of Biometrics ^*  (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; IMATINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFUSION; DEHYDRATION; DELUSION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HALLUCINATION; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LETHARGY; LEUKOPENIA; MALAISE; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PSYCHOSIS; SKIN BRUISING; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84867864604     PISSN: 19347820     EISSN: 19347987     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Janes RH Jr, Niedenrhuber JE, Chmiel JS, et al: National patterns of care for pancreatic cancer: results of a survey by the Commission on Cancer. Ann Surg 223:261-272, 1996
2. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413, 1997
3. Moore MJ, Goldstein D, Hamm J: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966, 2007
4. Heinemann V, Boeck S, Hinke A, et al: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82, 2008
5. Heinemann V, Labianca R, Hinke A, et al: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 18:1652-1659, 2007
6. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for meta-static pancreatic cancer. N Engl J Med 364: 1817-1825, 2011
7. Tabernero J, Macarulla T: Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol 27:5487-5491, 2009
8. Kinoshita K, Nakagawa K, Hamada J, et al: Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. Int J Oncol 37:869-877, 2010
9. Carroll M, Ohno-Jones S, Tamura S, et al: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90: 4947-4952, 1997
10. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABh tyrosine kinase in chronic myeloid leukemia. N EnglJ Med 344:1031-1037, 2001
11. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N EnglJ Med 347:472-480, 2002
12. Gharibo M, Patrick-Miller L, Zheng L, et al: A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer. Pancreas36: 341-345, 2008
13. Chen J, Rocken C, Nitsche B, et al: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett 233:328-337, 2006
14. Coleman RL, Broaddus RR, Bodurka DC, et al: Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101:126-131, 2006
15. Dy GK, Miller AA, Mandrekar SJ, et al: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16: 1811-1816, 2005
16. Einhorn LH, Brames MJ, Heinrich MC, et al: Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 29:12-13, 2006
17. Johnson BE, Fischer T, Fischer B, et al: Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9:5880-5887, 2003
18. Modi S, Seidman AD, Dickler M, et al: A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 90:157-163, 2005
19. Rao K, Goodin S, Levitt MJ, et al: A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate 62:115-122, 2005
20. Wyman K, Atkins MB, Prieto V, et al: Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significanttoxicity with no clinical efficacy. Cancer 106:2005-2011, 2006
21. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316, 1999
22. Ostman A: PDGF receptors-mediators of auto-crine tumor growth and regulators of tumor vas-culature and stroma. Cytokine Growth Factor Rev 15:275-286, 2004
23. Kalthoff H, Roeder C, Humburg I, et al: Modulation of platelet-derived growth factor A- and B-chain/c-sis mRNA by tumor necrosis factor and other agents in adenocarcinoma cells. On-cogene 6:1015-1021, 1991
24. Kim R, Emi M, Arihiro K, et al: Chemosensitiza-tion by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 103:1800-1809, 2005
25. Pietras K, Rubin K, Sjoblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484, 2002
26. Hwang RF, Yokoi K, Bucana CD, et al: Inhibition of platelet-derived growth factor receptor phos-phorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 9:6534-6544, 2003
27. Yasuda A, Sawai H, Takahashi H, et al: The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer 5:6534-46, 2006
28. Li J, Kleeff J, Guo J, et al: Effects of STI571 (gleevec) on pancreatic cancer cell growth. Mol Cancer 2:6534-32, 2003
29. Bertino P, Piccardi F, Porta C, et al: Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xe-nografts. Clin Cancer Res 14:541-548, 2008
30. Yokoi K, Sasaki T, Bucana CD, et al: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res 65:10371-10380, 2005
31. Melisi D, Ishiyama S, Sclabas GM, et al: LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Therl 7 829-840, 2008
32. George S, Desai J, Paul Eder J, et al: Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. Eur J Cancer42:864-870, 2006
33. Ali Y, Lin Y, Gharibo MM, et al: Phase I and pharmacokinetic study of imatinib mesylate (gleevec) and gemcitabine in patients with refractory solid tumors. Clin Cancer Res 13:5876-5882, 2007
34. Ferrigno D, Buccheri G: Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer 29:91-104, 2000
35. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
36. Cockcroft DW, Gault MH: Prediction of creati-nine clearance from serum creatinine. Nephron 16:31-41, 1976
37. Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxalip-latin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute nfusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol27:3778-3785, 2009
38. Brand R, Capadano M, Tempera M: A phase trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15:331-341, 1997
39. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127-1134, 2004
40. Von Hoff DD, Ramanathan R, Borad M, et al: SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase l/lI study. 2009 ASCO Annual Meeting. J Clin Oncol 27:15S, 2009 (abstr 4525)
41. Hidalgo M, Maitra A: The hedgehog pathway and pancreatic cancer. N Engl J Med 361; 2094-2096, 2009
42. Nilsson B, Hendlisz A, Castella M, et al: First-in-human study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumors. 2009 ASCO Annual Meeting. J Clin Oncol 27:2094-15S, 2009 (abstr 2577)